Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-02-07
2010-11-30
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07842702
ABSTRACT:
N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide is effective for treating IBS. In addition, IBS may be effectively treated with N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide when used concomitantly with at least one of various serotonin 5-HT3 receptor antagonists.
REFERENCES:
patent: 2005/0192329 (2005-09-01), Nishida et al.
patent: 0 157 346 (1985-10-01), None
patent: 0 811 378 (1997-12-01), None
patent: 6-256187 (1994-09-01), None
patent: WO 94/07491 (1994-04-01), None
patent: WO 95/21611 (1995-08-01), None
patent: WO2004062623 (2004-07-01), None
patent: WO 2006/122069 (2006-11-01), None
Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
T. Imai, et al., “Effects of a novel orally-active antiallergic drug, quinotolast (FK021), on airway clearance, Nippon yakurigaku zasshi” Folia Pharmacologica Japonica, vol. 104, No. 4, 1994, pp. 347-355 (with English abstract and a partial English translation).
Javier Santos, et al., “Targeting mast cells in the treatment of functional gastrointestinal disorders”, Current Opinion in Pharmacology, vol. 6, No. 6, 2006, pp. 541-546.
Susan K. Hadley, et al., “Treatment of Irritable Bowel Syndrome”, American Family Physician, vol. 72, No. 12, Dec. 15, 2005, pp. 2501-2506.
C. Lunardi, et al., “Double-Blind Cross-Over Trial of Oral Sodium Cromoglycate in Patients With Irritable Bowel Syndrome Due to Food Intolerance”, Clinical and Experimental Allergy, vol. 21, 1991, pp. 569-572.
G. F. Stefanini, et al., “Oral Disodium Cromoglycate Treatment on Irritable Bowel Syndrome: An Open Study on 101 Subjects With Diarrheic Type”, The American Journal of Gastroenterology, vol. 87, No. 1, 1992, pp. 55-57.
G. F. Stefanini, et al., “Oral Cromolyn Sodium in Comparison With Elimination Diet in the Irritable Bowel Syndrome, Diarrheic Type”, Scandinavian Journal of Gastroenterology, vol. 30, 1995, pp. 535-541.
Jun-Ho La, et al., “Role of Mucosal Mast Cells in Visceral Hypersensitivity in a Rat Model of Irritable Bowel Syndrome”, Journal of Veterinary Science, vol. 5, No. 4, 2004, pp. 319-324.
Katsumasa Kobayashi, et al., “Effects of Quinotolast, A New Orally Active Antiallergic Drug, on Experimental Allergic Models”, Japanese Journal of Pharmacology, vol. 63, 1993, pp. 73-81.
T. Mori, et al., “Pro-drugs for the Oral Delivery of Disodium Cromoglycate”, vol. 36 (1), pp. 338-344 (1988).
L. Ramos, et al., AGA Abstracts, Abstract No. 325, p. A-60-A61 (2007).
S.D. Kuiken et al.,Aliment. Pharmacol. Ther., vol. 22, pp. 157-164 (2005).
I. Posserud et al.,Gastroenterology, vol. 133, pp. 1116-1123 (2007).
Doihara Hitoshi
Ito Hiroyuki
Suzuki Jotaro
Takezawa Ryuichi
Astellas Pharma Inc.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Spivack Phyllis G.
LandOfFree
Treatment for irritable bowel syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for irritable bowel syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for irritable bowel syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207362